Genetic Deficiency of Glycogen Synthase Kinase-3β Corrects Diabetes in Mouse Models of Insulin Resistance

Despite treatment with agents that enhance β-cell function and insulin action, reduction in β-cell mass is relentless in patients with insulin resistance and type 2 diabetes mellitus. Insulin resistance is characterized by impaired signaling through the insulin/insulin receptor/insulin receptor substrate/PI-3K/Akt pathway, leading to elevation of negatively regulated substrates such as glycogen synthase kinase-3β (Gsk-3β). When elevated, this enzyme has antiproliferative and proapoptotic properties. In these studies, we designed experiments to determine the contribution of Gsk-3β to regulation of β-cell mass in two mouse models of insulin resistance. Mice lacking one allele of the insulin receptor (Ir+/−) exhibit insulin resistance and a doubling of β-cell mass. Crossing these mice with those having haploinsufficiency for Gsk-3β (Gsk-3β+/−) reduced insulin resistance by augmenting whole-body glucose disposal, and significantly reduced β-cell mass. In the second model, mice missing two alleles of the insulin receptor substrate 2 (Irs2−/−), like the Ir+/− mice, are insulin resistant, but develop profound β-cell loss, resulting in early diabetes. We found that islets from these mice had a 4-fold elevation of Gsk-3β activity associated with a marked reduction of β-cell proliferation and increased apoptosis. Irs2−/− mice crossed with Gsk-3β+/− mice preserved β-cell mass by reversing the negative effects on proliferation and apoptosis, preventing onset of diabetes. Previous studies had shown that islets of Irs2−/− mice had increased cyclin-dependent kinase inhibitor p27kip1 that was limiting for β-cell replication, and reduced Pdx1 levels associated with increased cell death. Preservation of β-cell mass in Gsk-3β+/−Irs2−/− mice was accompanied by suppressed p27kip1 levels and increased Pdx1 levels. To separate peripheral versus β-cell–specific effects of reduction of Gsk3β activity on preservation of β-cell mass, mice homozygous for a floxed Gsk-3β allele (Gsk-3F/F) were then crossed with rat insulin promoter-Cre (RIP-Cre) mice to produce β-cell–specific knockout of Gsk-3β (βGsk-3β−/−). Like Gsk-3β+/− mice, βGsk-3β−/− mice also prevented the diabetes of the Irs2−/− mice. The results of these studies now define a new, negatively regulated substrate of the insulin signaling pathway specifically within β-cells that when elevated, can impair replication and increase apoptosis, resulting in loss of β-cells and diabetes. These results thus form the rationale for developing agents to inhibit this enzyme in obese insulin-resistant individuals to preserve β-cells and prevent diabetes onset.


Introduction
Despite treatment with agents that enhance b-cell function and insulin action, reduction in b-cell mass is relentless in type 2 diabetes (T2DM) [1][2][3][4]. Why b-cells fail in some individuals is a central issue in diabetes research today. The molecular mechanisms enabling b-cell adaptation to insulin resistance are being discovered primarily in animal models [5][6][7]. Important genetic models have focused on the requirement for insulin signaling through b-cell insulin/insulin-like growth factor 1 (IGF1) receptors (reviewed in [8,9]). Whereas mice with total-body deficiency for insulin receptor substrate 1 (Irs1 À/À ) have insulin resistance and significant expansion of bcell mass, insulin receptor substrate 2-deficient mice (Irs2 À/À ) have insulin resistance yet develop postnatal b-cell loss and severe diabetes (reviewed in [10]). In this model and in others, the primacy of PI-3K/Akt activity in expansion and postnatal maintenance of b-cell mass was apparent (reviewed in [11,12]). The remarkable ability of b-cell mass to expand via enhanced proliferation and reduced apoptosis was demonstrated in transgenic mice expressing constitutively active Akt in b-cells [13,14], illustrating the potential importance of this pathway for expanding b-cells in patients and perhaps resisting the apoptosis that accompanies long-standing diabetes. Knowing that increased expression of Akt in b-cells leads to marked expansion, these results have focused interest on the role of two negatively regulated Akt substrates, FoxO1 and Gsk-3b, each known to regulate carbohydrate and lipid metabolism in insulin target tissues while also exhibiting antiproliferative and proapoptotic properties when expressed at high levels [15,16]. There is substantial evidence, mostly from overexpression of a constitutively nuclear FoxO1, that FoxO1 has detrimental effects on b-cell proliferation and survival [17]. On the other hand, there is little known about the effects of expression of Gsk-3b on b-cell proliferation and/or survival.
Gsk-3 activity has been shown to be increased in peripheral tissues in diabetic animals and patients [30][31][32], and diabetes was reversed in obese diabetic mice treated with Gsk-3 inhibitors [33][34][35]. Because inhibitors have differing degrees of kinase specificity, Gsk-3-deficient genetic models were created. Disruption of the Gsk-3b gene in mice results in embryonic lethality [23], yet mice with loss of one allele (Gsk-3b þ/À ) are viable and express reduced levels of protein and enzymatic activity [23]. Although Gsk-3b þ/À mice have been little studied, they have been shown to have behavioral effects similar to lithium-treated mice, suggesting that Gsk-3b is the main determinant of Gsk-3 activity in the nervous system [36]. The availability of these Gsk-3b þ/À mice provided the opportunity to assess the role of Gsk-3b on insulin sensitivity and pancreatic b-cell function.
Mice haploinsufficient for the insulin receptor (Ir þ/À ) have insulin resistance with expanded islet b-cell mass and hyperinsulinemia [37]. Crossing Ir þ/À mice with mice haploinsufficient for FoxO1 (Foxo1 þ/À ) improved insulin sensitivity and reduced islet mass [17]. In the current study, we hypothesized that in Ir þ/À mice, increased Gsk-3b as well as FoxO1 activity could be contributing to the insulin-resistant phenotype. We crossed Ir þ/À mice with mice lacking one allele of Gsk-3b (Gsk-3b þ/À ) and found that Gsk-3b þ/À Ir þ/À mice, like Foxo1 þ/À Ir þ/À mice, also had improved insulin sensitivity and reduced b-cell mass. Next, we investigated a mouse that is missing two alleles of the insulin receptor substrate 2 (Irs2 À/À ), that is also insulin resistant, but develops profound b-cell destruction resulting in marked diabetes [38]. Although crossing Irs2 À/À mice with Foxo1 þ/À mice increased b-cell mass and proliferation [39], suggesting that increased b-cell FoxO1 activity was contributing to b-cell loss in Irs2 À/À mice, we found that Gsk-3b activity in islets of Irs2 À/À mice was also markedly elevated. We determined that Gsk-3b þ/À Irs2 À/À mice had reduced, but persistent, insulin resistance, yet do not develop diabetes, as a result of maintaining islet b-cell mass. Preservation of b-cell mass in Gsk-3b þ/À Irs2 À/À mice appeared to be due to accelerated proliferation and decreased apoptosis of b-cells. Reduction of Gsk-3b, like reduction of FoxO1, results in preservation of bcell mass and rescues the diabetes in this model. The results of these studies now define a new, negatively regulated substrate of the insulin signaling pathway specifically within b-cells that when elevated, can impair replication and increase apoptosis, resulting in loss of b-cells and diabetes.

Results
Gsk-3b Deficiency (Gsk-3b þ/À ) Promotes Insulin Sensitivity and Reduces the Hyperinsulinemia of Insulin Receptor-Deficient Mice (Ir þ/À ) To determine whether Gsk-3b is a downstream contributor to the insulin resistance of insulin receptor-deficient mice, Gsk-3b þ/À mice were crossed with mice missing one allele of the insulin receptor (Ir þ/À ), previously shown to have insulin resistance and elevation of insulin levels in adult animals [37]. Fasting and fed glucose and insulin levels were assessed in Gsk-3b þ/À , Ir þ/À , and compound heterozygous (Gsk-3b þ/À Ir þ/À ) mice and compared to levels in wild type (WT) at 26 wk of age ( Figure 1A). Both fasting and fed insulin levels were significantly reduced in mice lacking one allele of Gsk-3b, thus indicating that genetic deficiency of Gsk-3b activity improves insulin sensitivity. In Ir þ/À mice, both fasting and fed insulin levels were higher than in WT mice, consistent with previous reports [37]. In compound heterozygous Gsk-3b þ/À Ir þ/À mice, the serum insulin values were significantly decreased relative to those in Ir þ/À mice in both the fasting and the fed state, although the values were significantly elevated relative to that in Gsk-3b þ/À mice (p , 0.05), suggesting that Gsk-3b þ/À Ir þ/À mice are still insulin resistant. Similar differences in glucose and insulin values were observed in mice at 8-10 wk of age ( Figure  S1A and S1B). Gsk-3b þ/À Ir þ/À mice were found to exhibit improved glucose tolerance relative to that in Ir þ/À mice ( Figure S1C). The results of these experiments thus indicate that (1) endogenous Gsk-3b activity contributes to ambient insulin sensitivity, and (2) that Gsk-3b activity is a downstream mediator of the insulin resistance of the Ir þ/À mice.
Gsk-3b þ/À Ir þ/À Mice Exhibit Enhanced Peripheral Insulin-Mediated Glucose Disposal and Reduced b-Cell Mass Relative to Ir þ/À Mice To further characterize the apparent improvement of insulin sensitivity, hyperinsulinemic-euglycemic clamps were

Author Summary
Diabetes is often characterized by a failure of insulin production by pancreatic b-cells to properly regulate glucose homeostasis. Insulin resistance can lead to b-cell failure, and our studies have focused on elucidating the mechanisms involved in this postnatal failure. In this study, we evaluated a new, negatively regulated enzyme of the insulin signaling pathway, glycogen synthase kinase 3 (Gsk-3), specifically within insulin-producing pancreatic b-cells. When this enzyme is elevated, it can impair replication and increase cell death, resulting in loss of insulin-producing cells and diabetes. Gsk-3 is also known to regulate cell death and proliferation in neurons. We assessed the role of Gsk-3 on glucose homeostasis in two different mouse models of insulin resistance. We demonstrated that genetically reducing the levels of Gsk-3b in the insulin-resistant mouse improved glucose homeostasis. In another model in which severe insulin resistance is associated with destruction of b-cells, reducing Gsk-3b not only preserved b-cells by increasing proliferation and reducing cell death, but it also corrected diabetes. Controlling activity of Gsk-3 could lead to new hopes for maintaining or improving b-cell number and prevention of diabetes.
performed. The rates of glucose disposal and glucose infusion were increased in Gsk-3b þ/À Ir þ/À mice relative to those in Ir þ/À mice, confirming enhanced insulin sensitivity ( Figure 1C and 1D). Hepatic glucose production did not appear to differ between Ir þ/À mice and Gsk-3b þ/À Ir þ/À mice ( Figure 1E Figures 2A-2D. Akthough there were no differences in pancreatic areas (unpublished data), the bcell mass was increased in Ir þ/À mice as previously noted [37], and reduced in Gsk-3b þ/À Ir þ/À mice as assessed by pancreatic morphometry ( Figure 2E). In conclusion, mice missing one allele of Gsk-3b when crossed with Ir þ/À mice had reduced hyperinsulinemia associated with reduced b-cell mass.

Gsk-3b Haplodeficiency in Irs2 À/À Mice Corrects Diabetes
Because of the antiproliferative and proapoptotic effects of Gsk-3b activity in other tissues [16], finding increased Gsk-3b activity in islets from Irs2 À/À mice was consistent with the possibility that this may contribute to the decreased b-cell mass and function of these mice. We therefore crossed mice haploinsufficient for Gsk-3b with Irs2 À/À mice to determine whether it would have beneficial effects on preserving b-cell mass and prevent diabetes. We generated double knockout mice (Gsk-3b þ/À Irs2 À/À ) by interbreeding Gsk-3b þ/À and Irs2 þ/À mice. The Irs2 À/À mice gained weight until about 9 wk, when body weight plateaued and began to decline. In contrast, the Gsk-3b þ/À Irs2 À/À mice continued to increase body weight, indistinguishable from that of the WT or Gsk-3b þ/À mice at 12 wk ( Figure 3C) and at 24 wk ( Figure S2A).
To interpret the basis for plasma insulin levels, insulin sensitivity was examined in Irs2 À/À and Gsk-3b þ/À Irs2 À/À mice relative to that in WT mice by insulin tolerance testing in 6wk-old mice ( Figure 3E). Interestingly, the Gsk-3b þ/À Irs2 À/À mice maintained insulin resistance relative to that in WT mice, suggesting that the beneficial effects of genetic deficiency of Gsk-3b on restoration of glucose homeostasis is not solely due to altered insulin sensitivity.
b-Cell Mass Is Preserved in Gsk-3b þ/À Irs2 À/À Mice Islet morphology in mice of each genotype was assessed at 8 wk of age. Immunostaining for insulin and glucagon on pancreatic sections are shown in Figure 4A-4F. The insulin immunoreactive area in Irs2 À/À mice was severely reduced ( Figure 4B and 4E) relative to that in Gsk-3b þ/À mice, consistent with previous reports [38,39]. In contrast, there appeared to be preservation of b-cell mass in the Gsk-3b þ/À Irs2 À/À mice ( Figure 4C and 4F). As quantified in Figure 4G, islet mass of Irs2 À/À mice was reduced to 30% of WT and Gsk-3b þ/À mice, whereas the mass of Gsk-3b þ/À Irs2 À/À mice did not differ from that of the control mice. Although the a-cell mass was not Figure 2. b-Cell Mass in WT, Gsk-3b þ/À , Ir þ/À , or Gsk-3b þ/À Ir þ/À (A-D) Pancreatic sections from 10-mo-old mice of the indicated genotypes were stained with antibodies to insulin and then were counterstained with hematoxylin. Scale bar represents 100 lm. (E) Random sections of the entire pancreas from 10-mo-old mice of the indicated genotypes were stained with hematoxylin and were measured to determine the b-cell mass (WT: n ¼ 3, Gsk-3b þ/À : n ¼ 3, Ir þ/À : n ¼ 4, and Gsk-3b þ/À Ir þ/À : n ¼ 4). Results are expressed as b-cell mass (mg). All values are represented as the mean 6 S.E.M. A single asterisk (*) indicates p , 0.05. doi:10.1371/journal.pbio.0060037.g002 determined, the reduction in bto a-cell ratio ( Figure 4H) was consistent with the reduction in b-cell mass.
(H) Quantification of the b/a cell ratio is shown. (WT: n ¼ 3, Gsk-3b þ/À : n ¼ 4, Irs2 À/À : n ¼ 5, and Gsk-3b þ/À Irs2 À/À : n ¼ 5 of the cyclin-dependent kinase inhibitor p27 kip1 in b-cells, and the loss of b-cell mass and diabetes was corrected when these mice were placed on a p27 kip1 null background [40]. This established p27 kip1 as a rate-limiting determinant of proliferation in this insulin-resistant model. Interestingly, it was recently shown that in non-b-cells, Gsk-3b stabilizes p27 kip1 [44]. We confirmed that islets of Irs2 À/À mice have increased p27 kip1 protein, and found that the increased proliferation in b-cells of Gsk-3b þ/À Irs2 À/À mice was associated with decreased p27 kip1 levels ( Figure 6B). Immunostaining on islets of WT mice revealed that only some of the islet cells were positive for p27 kip1 (Figure 6D, left). In contrast, virtually all of the nuclei of the islet cells in Irs2 À/À mice were positive ( Figure 6D, middle). In Gsk-3b þ/À Irs2 À/À mice, p27 kip1 could only be detected in some of the nuclei of the islet cells ( Figure 6D, right), with a staining that appears to be weaker than observed in Irs2 À/À mice, consistent with the increased proliferation observed in these mice.

Gsk-3 Activity Stabilizes p27 kip1 in Mouse Insulinoma Cells and in Primary Mouse Islets
To further examine effects of reduction in Gsk-3 activity on protein stability of p27 kip1 , mouse insulinoma cells were pretreated with lithium to inhibit Gsk-3 activity, and protein levels were assayed 4 h after addition of cyclohexamide to inhibit new protein synthesis. Lithium treatment reduced Gsk-3 activity and markedly reduced levels of p27 kip1 compared to cells treated with NaCl as an osmotic control ( Figure 8A).
To confirm the physiological significance of the effects of Gsk-3 activity on p27 kip1 levels, primary mouse islets were examined. Islets were isolated from WT mice and incubated for 4 h in serum-free medium, followed by 3 h with no addition, or with the addition of either IGF-1 to activate the insulin signaling pathway, with lithium, or with both, or islet protein lysates blotted for p27 kip1 levels ( Figure 8B). Addition of IGF-1 and lithium resulted in reduced p27 kip1 levels, with maximum reduction with addition of both. These results provide physiological support for the conclusion that Gsk-3 activity stabilizes p27 kip1 levels in pancreatic islets.

Discussion
The current study offers specific genetic approaches to assess the role of Gsk-3b in control of b-cell mass in insulin-resistant diabetic models, and as a consequence, several novel observations were made. Loss of one allele of Gsk-3b in WT mice promotes insulin sensitivity and in Ir þ/À mice reduces insulin resistance and improves glucose tolerance by enhancing glucose disposal. Severely insulin-resistant Irs2 À/À mice were found to have elevated islet Gsk-3 activity associated with severe reduction of b-cell proliferation and elevated apoptosis. Loss of one allele of Gsk-3b in Irs2 À/À mice reversed these findings, preserving b-cell mass and preventing diabetes. Additionally, Pdx1 levels were depressed and p27 Kip1 levels were increased in islets of Irs2 À/À mice, and they were also reversed by loss of one allele of Gsk-3b. b-cell-specific deficiency of Gsk-3b reversed the diabetes of the Irs2 À/À mice, indicating the importance of Gsk-3b in islet b-cells. Finally, in vitro studies demonstrated that Gsk-3 activity stabilizes p27 kip1 levels, suggesting a mechanism for impairment of proliferation. The results of these studies thus indicate that in insulin-resistant animals, Gsk-3b impairs replication and enhances cell death, leading to postnatal b-cell loss and diabetes.
FoxO1 and Gsk-3b are both negatively regulated targeted proteins of the insulin/PI-3K/Akt signaling pathway. Previous studies showed that Irs2 À/À mice crossed with Foxo1 þ/À mice resulted in partial correction of fed plasma glucose, b-cell mass, and proliferation [39], along with improved Pdx1 expression. In the current study, we found that islets of Irs2 À/À mice had increased Gsk-3 activity ( Figure 3A and 3B), now demonstrating that both Gsk-3 and FoxO1 significantly contribute to the impaired proliferation and increased apoptosis in Irs2 À/À mice.
What are the mechanisms that could account for postnatal loss of b-cell mass in the insulin-resistant models? Evidence to date suggests that FoxO1 is contributing through impaired proliferation and enhanced apoptosis via transcriptional mechanisms, as it has been shown to repress Pdx1 transcription in insulinoma cells [39]. In non-b-cells FoxO1 has also been shown to increase p27 Kip1 expression [45]. The results of the current studies suggest a novel mechanism for regulation of Pdx1 and p27 Kip1 levels in insulin-resistant bcells through Gsk-3b activity. In non-b-cells, the half-life (t 1/2 ) of p27 Kip1 protein was 12 h in the absence of growth factors, and 20 min when growth factors were restored, or when cells were treated with Gsk-3b inhibitors [44]. Gsk-3b phosphorylated and stabilized p27 Kip1 , whereas Gsk-3b inhibitors targeted p27 Kip1 for proteosomal degradation. These results suggest a possible mechanism by which Gsk-3 activity might regulate cell proliferation in b-cells through altered p27 Kip1 stability. There is substantial evidence that this mechanism is operational in b-cells. First, p27 kip1 levels were increased in islets from Irs2 À/À mice ( Figure 6B and 6D, and [40]), and levels were reduced with elimination of one allele of Gsk-3b. Figure 6. Effects of Inhibition of Gsk-3b Activity on Pdx1 and p27 kip1 Expression in Islets from Irs2 À/À Mice Islets were isolated from 6 wk-old WT, Gsk-3b þ/À Irs2 À/À , and Irs2 À/À mice. (D) Immunostaining for p27 kip1 in pancreatic islets of 8-wk-old WT, Irs2 À/À , and Gsk-3b þ/À Irs2 À/À mice. Hematoxylin counterstaining reveals nucleus in dark blue (and acinar cells in light blue); p27 kip1 staining is in red. Scale bars represent 50 lm. doi:10.1371/journal.pbio.0060037.g006 Second, in vitro evidence is presented showing that Gsk-3 activity regulates p27 Kip1 protein stability in insulinoma cells ( Figure 8A). Third, physiological support for the conclusion that Gsk-3 activity stabilizes p27 kip1 levels in pancreatic islets is presented ( Figure 8B). In contrast to p27 Kip1 protein stabilization, Gsk-3 activity was shown to destabilize Pdx1 protein levels in insulinoma cells [46]. We have confirmed this effect of Gsk-3 activity on Pdx1 in MIN6 cells (unpublished data), and now provide in vivo evidence that reduction of islet Gsk-3b activity restores Pdx1 levels in islets of Gsk-3b þ/À Irs2 À/À mice ( Figure 6B and 6C).
The Irs2 À/À mice have severe impairment of the insulin signaling PI-3K/Akt pathway, and rapidly lose b-cell mass. Elimination of one allele of Gsk-3b in Irs2 À/À mice preserves b-cell mass and, for the most part, maintains glucose homeostasis, yet Gsk-3b is only one of many substrates regulated by the insulin signaling pathway. For example, Irs2 À/À mice have increased FoxO1 [39], and perhaps decreased S6K levels, along with alterations in other Akt substrates. Although the Gsk-3b þ/À Irs2 À/À mice maintain apparently normal b-cell mass, they are still insulin resistant, and therefore not fully functional; they would be anticipated to have expanded b-cell mass as shown in the Ir þ/À mice ( Figure 2E). Thus Gsk-3b is only one protein among many necessary for fully functional b-cells.
Elimination of one allele of Gsk-3b in insulin-resistant Ir þ/À mice enhanced insulin sensitivity by augmenting peripheral insulin-mediated glucose disposal, independent of effects on hepatic glucose output ( Figure 1C-1E). These results are consistent with those in which tissue-specific knockout of Gsk-3b in skeletal muscle enhanced insulin sensitivity (S. The results of these studies now define a new, negatively regulated substrate of the insulin signaling pathway specifically within b-cells that when elevated, can impair replication and increase apoptosis, resulting in postnatal loss of b-cells and diabetes. These results thus form the rationale for developing agents to inhibit this enzyme in obese insulin-resistant individuals to preserve b-cells and prevent diabetes onset.
Blood glucose as well as serum insulin concentrations were determined as previously described [13]. For the glucose tolerance test, mice were subjected to an overnight fast followed by intraperitoneal glucose injection (2.0 g/kg). Blood samples were collected at 0, 30, 60, and 120 min after the injection. For the insulin tolerance tests, mice were subjected to a 4-h fast followed by intraperitoneal human regular insulin injection (0.5 U/kg). Blood samples were collected 0, 30, 60, and 120 min after the injections. After sacrificing the mice, the pancreas was removed and weighed. All experiments were carried out with male mice. This project was approved by the Animal Ethics Committee of Washington University School of Medicine.
Hyperinsulinemic-euglycemic clamps. Clamp experiments were essentially performed as previously described [50,51]. Double-lumen catheters were placed and 3-[3H] glucose was infused to steady state. Regular human insulin was infused at 20 mU/kg per min with 25% Dglucose to maintain the blood glucose at 120 mg/dl for at least 90 min. The 3-[3H] glucose infusion was continued during the clamp, with labeled glucose included in the 25% D-glucose infusion to match blood specific activity at steady state. The rate of appearance of glucose (Ra), equal to the rate of glucose utilization (Rd) at steady state, was determined by dividing the infusion rate of labeled glucose by the specific activity. Endogenous glucose production was calculated by subtracting the cold glucose infusion rate from the clamp Rd.
Immunohistochemical and morphometric analysis of the pancreatic islets. Pancreas were isolated and fixed from 8-wk-old Irs2 À/À , Gsk-3b þ/À Irs2 À/À , and Gsk-3b þ/À mice. Isolated pancreas were fixed overnight in 3.7% formaldehyde at room temperature. Tissue was then routinely processed for paraffin embedding, and 5-lm sections were cut and mounted on glass slides. The sections were immunostained with antibodies to insulin (Dako), glucagon (Sigma Aldrich), Ki67 (Zymed Laboratories/Invitrogen), Pdx-1 (Joel Habener), and p27 kip1 (BD Transduction Laboratories). Histomouse-SP (Zymed Laboratories/Invitrogen) was used for secondary antibodies for brightfield microscopy and b-cell mass, whereas Cy3-or fluorescein isothiocya-nateÀconjugated (FITC) secondary antibodies (Jackson Immunoresearch) were used for fluorescence microscopy. All images were acquired on a DM4000 B microscope (Leica Microsystems). The b-cell area was determined after the analysis of a number of random sections stained for insulin and analyzed with NIH Image 1.38x software [52]. The total b-cell mass was then calculated using the following calculation: [(islet area/total pancreas area) 3 pancreas weight]. Five pancreatic sections from each animal, including representative sections of pancreas, and at least 100 islets per mouse were counted. Adjacent nonoverlapping fields were analyzed to obtain a true representation of average islet/b cell distribution throughout the pancreas.
TUNEL staining was performed on pancreatic sections using the ApopTag in situ apoptosis detection kit and according to the manufacturer's instructions (Chemicon/Milipore). At least 3,000 insulin-positive cells were counted for each mouse to assess the percentage of TUNEL-positive cells among insulin-positive cells.
Quantitative data are obtained from at least three mice in each group, unless indicated.
For immunoblot analysis with mouse insulinoma MIN6 cells, lysates of MIN6 cells treated with either 40 mM lithium or 40 mM NaCl for 1 h, then cotreated with 25 lg/ml cyclohexamide and lithium for 4 h, were prepared. The lysates were probed with the antibodies listed above.
Islets isolated from 16-wk-old WT mice were deprived of serum for 4 h and were incubated in the absences or presence of 10% FBS, 100 nM IGF-1, or 40 mM LiCl for 3 h. Lysates were then prepared from islets and were subjected to western blot analysis with the antibodies listed above.
Immune complexes were revealed using ECL Advance Western Blot Detection kit (Amersham), and the images were acquired using a FluoroChemi 8800 digital camera acquisition system (Alpha Innotech). Band intensities in the blots were later quantified using ImageJ 1.39j [53] and a-tubulin or b-actin bands were used to adjust for loading differences.